Alteration of Autophagy and Glial Activity in Nilotinib-Treated Huntington’s Disease Patients

Nilotinib is a tyrosine kinase inhibitor that is safe and tolerated in neurodegeneration, it achieves CSF concentration that is adequate to inhibit discoidin domain receptor (DDR)-1. Nilotinib significantly affects dopamine metabolites, including Homovanillic acid (HVA), resulting in an increase in...

Full description

Bibliographic Details

Published in:	Metabolites
Main Authors:	Karen E. Anderson, Max Stevenson, Rency Varghese, Michaeline L. Hebron, Erin Koppel, Mara McCartin, Robin Kuprewicz, Sara Matar, Dalila Ferrante, Charbel Moussa
Format:	Article
Language:	English
Published:	MDPI AG 2022-12-01
Subjects:	nilotinib Huntington’s DDR1 dopamine miRNA autophagy
Online Access:	https://www.mdpi.com/2218-1989/12/12/1225